阿司匹林用于心血管疾病和结直肠癌预防:美国预防服务工作组更新建模研究
该研究为美国预防服务工作组(USPSTF)更新2016年推荐而进行的微模拟建模研究,模拟40至79岁、无心血管疾病史且无出血风险升高、10年动脉粥样硬化性心血管事件风险最高20%的美国人群队列。低剂量(≤100 mg/d)阿司匹林终身使用,并按65至85岁每5年间隔设定停药年龄。主要结局为终身净获益(质量调整生命年QALYs和生命年)。结果显示,40至59岁起始且10年心血管风险≥5%、或60至69岁起始且风险≥10%时,净QALYs为正;终身净生命年在多数60至79岁起始者中为负,70至79岁起始者净QALYs亦为负。
要点
- 40至59岁起始、10年心血管风险≥5%者,终身净QALYs为正,范围为每1000人2.3(95% CI, -2.7至7.4)至66.2(95% CI, 58.2至74.1)QALYs。
- 60至69岁起始、10年心血管风险≥10%者,终身净QALYs为正。
- 60至79岁起始阿司匹林者,多数情况下终身净生命年为负;70至79岁起始者净QALYs为负。
- 在65至85岁之间停用阿司匹林,与终身使用相比通常优势很小。
- 敏感性分析提示,若阿司匹林降低结直肠癌发病率或心血管死亡率,净获益可能更高;若增加致死性大出血或降低生活质量,净获益可能更低。
适用人群与场景
- 模拟美国40至79岁男女人群,10年动脉粥样硬化性心血管事件风险最高20%,无既往心血管疾病史,无出血风险升高。
诊断标准与关键阈值
- 10年心血管疾病风险阈值:5%或10%(用于定义净获益转正的风险界值)。
- 起始年龄分层:40至59岁、60至69岁、70至79岁。
- 停药年龄:65至85岁,每5年间隔。
处置流程与药物剂量
- 低剂量阿司匹林≤100 mg/d,终身使用,除非发生出血事件而禁忌。
- 起始年龄与10年心血管风险条件:40至59岁且风险≥5%时净QALYs为正;60至69岁且风险≥10%时净QALYs为正。
- 停药年龄可在65至85岁之间每5年间隔选择,但与终身使用相比通常优势很小。
研究设计与关键结果
- 研究设计:微模拟建模研究,模拟美国40至79岁男女人群,10年动脉粥样硬化性心血管事件风险最高20%,无既往心血管疾病史,无出血风险升高。
- 干预:低剂量(≤100 mg/d)阿司匹林终身使用,除非发生出血事件而禁忌;停药年龄设定为65至85岁,每5年间隔。
- 主要终点:终身净QALYs和净生命年。
- 终身净QALYs在40至59岁起始且10年心血管风险≥5%、或60至69岁起始且风险≥10%时为正,范围为每1000人2.3(95% CI, -2.7至7.4)至66.2(95% CI, 58.2至74.1)QALYs。
- 终身净生命年在40至49岁起始的男性(风险≥5%)和女性(风险≥10%)中为正,在50至59岁起始的男性(风险≥7.5%)和女性(风险≥15%)中为正,范围为每1000人0.4(95% CI, -6.1至6.9)至52.4(95% CI, 43.9至60.9)生命年。
- 60至79岁起始阿司匹林者多数情况下终身净生命年为负;70至79岁起始者终身净QALYs为负。
- 在65至85岁之间停用阿司匹林与终身使用相比通常优势很小。
- 敏感性分析显示,若阿司匹林降低结直肠癌发病率或心血管死亡率,终身净获益可能更高;若阿司匹林增加致死性大出血或降低常规使用的生活质量,净获益可能更低。
证据类型、等级与局限
- 证据类型:微模拟建模研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该微模拟研究提示,部分人群可能从阿司匹林一级预防中获益,主要是较年轻起始且10年心血管风险较高者。
指南或共识出处
- 美国预防服务工作组(USPSTF)2016年阿司匹林用于心血管疾病和结直肠癌一级预防推荐(更新中)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The US Preventive Services Task Force (USPSTF) is updating its 2016 recommendation on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC).
OBJECTIVE: To provide updated model-based estimates of the net balance in benefits and harms from routine use of low-dose aspirin for primary prevention.
DESIGN, SETTING, AND PARTICIPANTS: Microsimulation modeling was used to estimate long-term benefits and harms for hypothetical US cohorts of men and women aged 40 to 79 years with up to 20% 10-year risk for an atherosclerotic CVD event and without prior history of CVD or elevated bleeding risks.
EXPOSURES: Low-dose (≤100 mg/d) aspirin for lifetime use, unless contraindicated by a bleeding event, and with stopping ages in 5-year intervals from age 65 to 85 years.
MAIN OUTCOMES AND MEASURES: Primary outcomes were lifetime net benefits measured in quality-adjusted life-years (QALYs) and life-years. Benefits included reduced nonfatal myocardial infarction and ischemic stroke. Harms included increased nonfatal major gastrointestinal bleeding and intracranial hemorrhage. Reduced CRC incidence was considered in sensitivity analysis.
RESULTS: Estimated lifetime net QALYs were positive for both men and women at 5% or greater 10-year CVD risk when starting between ages 40 and 59 years and at 10% or greater 10-year CVD risk when starting between ages 60 and 69 years. These estimates ranged from 2.3 (95% CI, -2.7 to 7.4) to 66.2 (95% CI, 58.2 to 74.1) QALYs per 1000 persons. Lifetime net life-years were positive for men at 5% or greater and women at 10% or greater 10-year CVD risk starting aspirin at ages 40 to 49 years and for men at 7.5% or greater and women at 15% or greater 10-year CVD risk at ages 50 to 59 years. These estimates ranged from 0.4 (95% CI, -6.1 to 6.9) to 52.4 (95% CI, 43.9 to 60.9) life-years per 1000 persons. Lifetime net life-years were negative in most cases for persons starting aspirin between ages 60 and 79 years, as were lifetime net QALYs for persons aged 70 to 79 years. Stopping aspirin between ages 65 and 85 years generally showed little advantage compared with lifetime use. Sensitivity analyses showed lifetime net benefits may be higher if aspirin reduced CRC incidence or CVD mortality and lower if aspirin increased fatal major gastrointestinal bleeding or reduced quality of life with routine use.
CONCLUSIONS AND RELEVANCE: This microsimulation study suggested that several population groups may benefit from taking aspirin for the primary prevention of CVD, primarily in persons starting at younger ages with higher 10-year CVD risk.
参考来源
- Dehmer SP, O'Keefe LR, Evans CV, et al. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. JAMA. 2022. PMID: 35471506. doi:10.1001/jama.2022.3385
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。